Robert Goldfarb
Geschäftsführer bei NEXIEN BIOPHARMA, INC.
Vermögen: 45 560 $ am 30.04.2024
Profil
Robert I.
Goldfarb is currently the President, Director & General Counsel at Accu-Break Pharmaceuticals, Inc. and the Director & General Counsel at Sustained Nano Systems LLC.
He is also a Member of The Florida Bar and the Chief Operating Officer at Nexien BioPharma, Inc. Previously, he served as a Director at Scion Cardio-Vascular, Inc. and NanoSystems LLC.
He was also the Chief Operating Officer at Kinder Holding Corp.
In addition, he worked as the Secretary, Senior Vice President & General Counsel at Andrx Corp.
from 2005 to 2006.
Prior to that, he was a Partner at Hughes Hubbard & Reed LLP from 1986 to 2000.
Mr. Goldfarb completed his undergraduate studies at the University of Connecticut and obtained a graduate degree from the University of Florida in 1980.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NEXIEN BIOPHARMA, INC.
3,38% | 25.09.2023 | 2 278 000 ( 3,38% ) | 45 560 $ | 30.04.2024 |
Aktive Positionen von Robert Goldfarb
| Unternehmen | Position | Beginn |
|---|---|---|
| NEXIEN BIOPHARMA, INC. | Geschäftsführer | - |
The Florida Bar
 The Florida Bar Miscellaneous Commercial ServicesCommercial Services The Florida Bar operates as professional organization of lawyers. The company is headquartered in Tallahassee, FL. | Corporate Officer/Principal | - |
Sustained Nano Systems LLC
 Sustained Nano Systems LLC Miscellaneous Commercial ServicesCommercial Services Sustained Nano Systems LLC is a company that develops products for post-cataract surgery treatment. The company is based in Westhampton Beach, NY and was founded by Barry M. Libin, who has been the CEO since incorporation. The company's products include dex-sa, which delivers dexamethasone to the subconjunctival space to treat postoperative inflammation and pain, and lat-la, a single extraocular injectable administration of a six-month release prostaglandin analog for glaucoma treatment. The company also develops SNS ret-la, which prevents blood vessel growth for over a year in a standard rabbit model of corneal angiogenesis. | Direktor/Vorstandsmitglied | 01.01.2011 |
Accu-Break Pharmaceuticals, Inc.
 Accu-Break Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Accu-Break Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The firm develops tablets that are designed to improve and enhance the functionality of pharmaceutical tablets. The company was founded in 2001 by Lawrence Solomon and David Lucking headquartered in Plantation, FL. | Präsident | 01.01.2007 |
Ehemalige bekannte Positionen von Robert Goldfarb
| Unternehmen | Position | Ende |
|---|---|---|
Andrx Corp.
 Andrx Corp. Pharmaceuticals: MajorHealth Technology Andrx Corp. developed, manufactured, and marketed oral pharmaceutical products. The company was founded in August, 1992 and was headquartered in Davie, FL. | General Counsel | 01.12.2006 |
Hughes Hubbard & Reed LLP
 Hughes Hubbard & Reed LLP Miscellaneous Commercial ServicesCommercial Services Hughes Hubbard & Reed LLP is engaged in the provision of legal services. Its services include corporate governance, merger and acquisition, capital markets, private equity, equipment finance & banking legal services. The company was founded by Charles Evan Hughes in 1884 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.01.2000 |
NanoSystems LLC
 NanoSystems LLC Information Technology ServicesTechnology Services NanoSystems LLC developed software solutions for surface inspection systems. The company was headquartered in Atlanta, GA. | Direktor/Vorstandsmitglied | - |
Kinder Holding Corp.
 Kinder Holding Corp. Financial ConglomeratesFinance Kinder Holding Corp. engages in the research and development of cannabis cannabinoid-based drugs for various medical conditions and disorders. It focuses on identifying the appropriate compounds for its myotonic and muscular diseases drug candidate. The company was founded on November 10, 1952 and is headquartered in San Marino, CA. | Geschäftsführer | - |
Scion Cardio-Vascular, Inc.
 Scion Cardio-Vascular, Inc. Medical SpecialtiesHealth Technology Scion Cardio Vascular, Inc. develops medical devices that facilitate procedures in the interventional cardio-vascular arena. Its products include Clo-Sur PAD, Future Products, Clo-Sur pad case study, Clo-Sur pad blind, Clo-Sur pad absorption and Clo-Sur pad removal. The company was founded in 1996 and is headquartered in Miami, FL. | Direktor/Vorstandsmitglied | - |
Ausbildung von Robert Goldfarb
| University of Connecticut | Undergraduate Degree |
| University of Florida | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NEXIEN BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Kinder Holding Corp.
Kinder Holding Corp. Financial ConglomeratesFinance Kinder Holding Corp. engages in the research and development of cannabis cannabinoid-based drugs for various medical conditions and disorders. It focuses on identifying the appropriate compounds for its myotonic and muscular diseases drug candidate. The company was founded on November 10, 1952 and is headquartered in San Marino, CA. | Finance |
Andrx Corp.
Andrx Corp. Pharmaceuticals: MajorHealth Technology Andrx Corp. developed, manufactured, and marketed oral pharmaceutical products. The company was founded in August, 1992 and was headquartered in Davie, FL. | Health Technology |
Scion Cardio-Vascular, Inc.
Scion Cardio-Vascular, Inc. Medical SpecialtiesHealth Technology Scion Cardio Vascular, Inc. develops medical devices that facilitate procedures in the interventional cardio-vascular arena. Its products include Clo-Sur PAD, Future Products, Clo-Sur pad case study, Clo-Sur pad blind, Clo-Sur pad absorption and Clo-Sur pad removal. The company was founded in 1996 and is headquartered in Miami, FL. | Health Technology |
Accu-Break Pharmaceuticals, Inc.
Accu-Break Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Accu-Break Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The firm develops tablets that are designed to improve and enhance the functionality of pharmaceutical tablets. The company was founded in 2001 by Lawrence Solomon and David Lucking headquartered in Plantation, FL. | Health Technology |
Hughes Hubbard & Reed LLP
Hughes Hubbard & Reed LLP Miscellaneous Commercial ServicesCommercial Services Hughes Hubbard & Reed LLP is engaged in the provision of legal services. Its services include corporate governance, merger and acquisition, capital markets, private equity, equipment finance & banking legal services. The company was founded by Charles Evan Hughes in 1884 and is headquartered in New York, NY. | Commercial Services |
NanoSystems LLC
NanoSystems LLC Information Technology ServicesTechnology Services NanoSystems LLC developed software solutions for surface inspection systems. The company was headquartered in Atlanta, GA. | Technology Services |
The Florida Bar
The Florida Bar Miscellaneous Commercial ServicesCommercial Services The Florida Bar operates as professional organization of lawyers. The company is headquartered in Tallahassee, FL. | Commercial Services |
Sustained Nano Systems LLC
Sustained Nano Systems LLC Miscellaneous Commercial ServicesCommercial Services Sustained Nano Systems LLC is a company that develops products for post-cataract surgery treatment. The company is based in Westhampton Beach, NY and was founded by Barry M. Libin, who has been the CEO since incorporation. The company's products include dex-sa, which delivers dexamethasone to the subconjunctival space to treat postoperative inflammation and pain, and lat-la, a single extraocular injectable administration of a six-month release prostaglandin analog for glaucoma treatment. The company also develops SNS ret-la, which prevents blood vessel growth for over a year in a standard rabbit model of corneal angiogenesis. | Commercial Services |
